Suzhou Forlong Biotechnology

Suzhou Forlong Biotechnology, based in Suzhou, China, is a biotechnology company. Suzhou Forlong Biotechnology (also styled Furong Biotech) develops next-generation cytokine drugs based on synthetic immunology, using platforms for long-acting optimisation, Fc engineering, AI-driven discovery and synthetic cytokine creation. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing FL115 in bladder & urothelial cancer. The largest, NCT07131202 (A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumours), plans to enrol 130 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.